NAD+ in the Age of GLP-1s: Supporting Metabolic Health at the Cellular Level

GLP-1 receptor agonists work at the hormonal level — suppressing appetite, slowing gastric emptying, and improving insulin secretion. NAD+ works at the cellular level — powering mitochondria, activating repair enzymes, and supporting the fundamental energy infrastructure of every cell.

These two approaches to metabolic health are complementary, not redundant. Understanding how they work together helps prescribers build more comprehensive programs and helps patients understand why the combination is more than the sum of its parts.

Both aging and obesity are associated with a decline in cellular energy metabolism:

In aging: NAD+ levels decline by approximately 50% between ages 40 and 60. Mitochondrial function deteriorates. Cells become less efficient at producing energy and less capable of repair.

In obesity: Chronic inflammation, oxidative stress, and metabolic dysfunction impair mitochondrial function. Insulin resistance reduces cellular glucose uptake. The result is a state of cellular energy deficit despite caloric excess.

GLP-1 therapy addresses the hormonal and metabolic consequences of obesity. NAD+ addresses the cellular energy infrastructure that underlies metabolic function. Together, they address the problem at multiple levels.

NAD+ is the primary electron carrier in the mitochondrial electron transport chain — the process by which cells convert nutrients to ATP (cellular energy). Without adequate NAD+, mitochondria cannot function efficiently.

Supplementing NAD+ (or its precursors NMN and NR) restores mitochondrial function in aged or metabolically stressed cells. The result: more efficient energy production, less oxidative stress, and better cellular function.

Sirtuins are NAD+-dependent enzymes that regulate metabolism, inflammation, and aging. There are seven sirtuins (SIRT1–SIRT7), each with distinct functions:

• SIRT1: Regulates insulin sensitivity, fat metabolism, and inflammation
• SIRT3: Regulates mitochondrial function and oxidative stress
• SIRT6: Regulates DNA repair and glucose metabolism

Higher NAD+ levels activate sirtuins, producing improvements in insulin sensitivity, reduced inflammation, and enhanced mitochondrial function — all directly relevant to GLP-1 patients.

PARP enzymes use NAD+ to repair DNA damage. Obesity and aging both increase DNA damage (through oxidative stress and inflammation). Adequate NAD+ supports the DNA repair capacity needed to maintain cellular health during the metabolic stress of weight loss.

GLP-1 therapy produces significant weight loss, but approximately 25–40% of the weight lost is lean mass. This muscle loss is a significant concern, particularly for older patients.

NAD+ supports muscle preservation through:

• SIRT1 activation (promotes muscle protein synthesis and reduces muscle protein breakdown)
• SIRT3 activation (improves mitochondrial function in muscle cells)
• Reduced inflammation (chronic inflammation accelerates muscle catabolism)

Patients on combined GLP-1 + NAD+ protocols may preserve more lean mass during weight loss — a clinically meaningful benefit.

GLP-1 titration is commonly associated with fatigue, particularly in the first 4–8 weeks. NAD+'s role in mitochondrial energy production means that NAD+ supplementation may help counteract this fatigue.

Both GLP-1 and NAD+ improve insulin sensitivity through different mechanisms:

• GLP-1: Glucose-dependent insulin secretion, reduced glucagon, improved beta-cell function
• NAD+: SIRT1 activation (improves insulin signaling), AMPK activation (improves glucose uptake), reduced inflammation

The combination may produce additive improvements in insulin sensitivity — particularly valuable for patients with metabolic syndrome or prediabetes.

Obesity is characterized by chronic low-grade inflammation that drives metabolic dysfunction. GLP-1 therapy reduces inflammation through weight loss and direct anti-inflammatory effects. NAD+ reduces inflammation through sirtuin activation and PARP-mediated DNA repair. The combination addresses inflammation through multiple pathways.

Oral NAD+ precursors (NMN, NR) are effective but have variable bioavailability. Subcutaneous NAD+ injection bypasses the GI tract entirely, delivering NAD+ directly into the bloodstream for maximum bioavailability.

For patients already comfortable with GLP-1 injections, adding sub-Q NAD+ is a natural extension of their existing injection routine.

Patient selection: GLP-1 patients who are concerned about muscle loss, fatigue, or long-term metabolic health are ideal candidates.

Positioning: "NAD+ supports the cellular energy infrastructure that makes your GLP-1 program more effective — helping preserve muscle, maintain energy, and support your long-term metabolic health."

Monitoring: Assess subjective response (energy, recovery, cognitive function) at 4-week and 8-week follow-ups.

Request portal access for NAD+ supply →

This content is for informational and educational purposes only. It does not constitute medical advice. Human evidence for NAD+ supplementation is still emerging. Prescribers should use clinical judgment.